Chloroquine increases phosphorylation of AMPK and Akt in myotubes

Larry D. Spears, Andrew V. Tran, Charles Y. Qin, Supriya B. Hobbs, Cheryl A. Liang Burns, Nathaniel K. Royer, Zhihong Zhang, Lyle Ralston, Jonathan S. Fisher

* Department of Biology, Saint Louis University, St. Louis, MO 63103, USA
* Sigma-Aldrich, St. Louis, MO 63103, USA
* Center for Cardiovascular Research, Saint Louis University, St. Louis, MO 63103, USA

* Corresponding author. Department of Biology and Center for Cardiovascular Research, Saint Louis University, 3507 Laclede Ave, St. Louis, MO 63103, USA.
E-mail address: fisherjs@slu.edu (J.S. Fisher).

Abstract

**Aims:** There are reports that ataxia telangiectasia mutated (ATM) can activate the AMP-activated protein kinase (AMPK) and also Akt, two kinases that play integral parts in cardioprotection and metabolic function. We hypothesized that chloroquine and resveratrol, both known ATM activators, would also activate AMPK and Akt.

**Main methods:** Phosphorylation of AMPK and Akt was assessed after C2C12 myotubes were exposed to chloroquine or resveratrol. Additional experiments were done in cells expressing shRNA against ATM or in the presence of the ATM inhibitor KU55933. The effects of chloroquine on intracellular calcium were assessed with the fluorescent probe Calcium Green-1 AM.

**Key findings:** 0.5 mM chloroquine increased AMPK phosphorylation by nearly four-fold ($P < 0.05$), and 0.25 mM chloroquine roughly doubled Akt phosphorylation ($P < 0.05$). Chloroquine also increased autophosphorylation of ATM by $\sim 50\%$ ($P < 0.05$). Resveratrol (0.15 mM) increased AMPK phosphorylation about three-fold ($P < 0.05$) but in contrast to chloroquine sharply decreased Akt phosphorylation. Chloroquine increased AMPK and Akt phosphorylation in myotubes expressing shRNA against ATM that reduced

http://dx.doi.org/10.1016/j.heliyon.2016.e00083
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ATM protein levels by about 90%. Likewise, chloroquine-stimulated phosphorylation of AMPK and Akt and resveratrol-stimulated phosphorylation of AMPK were not altered by inhibition of ATM. Chloroquine decreased intracellular calcium by >50% concomitant with a decrease in glucose transport. **Significance:** These ATM-independent effects of chloroquine on AMPK and Akt and the additional effect to decrease intracellular calcium are likely to partially underlie the positive metabolic effects of chloroquine that have been reported in the literature.

Keywords: Applied sciences, Therapeutics in cell biology, Animal metabolism

1. Introduction

Ataxia Telangiectasia (A-T) is an autosomal disease caused by mutations in the ataxia telangiectasia mutated (ATM) gene [1]. The ATM gene codes for a protein that is a serine-threonine kinase and a member of the phosphatidylinositol 3 kinase like kinase (PI3KK) family. In addition to ATM’s well-known functions in cell cycle control and response to DNA damage, ATM has increasingly been found to display a variety of metabolic functions. For example, ATM plays antioxidant roles by stimulating the pentose phosphate pathway [2] and through increasing uptake of dehydroascorbic acid (DHA) [3], the oxidized form of the potent antioxidant ascorbate. Mitochondrial dysregulation has been reported for ATM-null thymocytes, with features including disorganized mitochondrial structure, increased mitochondrial reactive oxygen species (ROS), and decreases in whole-cell ATP despite an increase in mitochondrial volume [4]. ATM has also been shown to play a role in insulin-stimulated glucose transport in cultured muscle cells and in skeletal muscle [5, 6, 7].

Two critical metabolic regulators in particular, the AMP-activated protein kinase (AMPK) and Akt seem to be central mediators of ATM’s metabolic functions. AMPK is a sensor of cellular energy status and responds to metabolic stress by activating diverse responses including an increase in fat oxidation [8] and an increase in expression and activity of mitochondrial proteins [9, 10]. ATM and AMPK appear to work in concert in response to cellular stress. For example, activity of both ATM and AMPK is required for the increase in insulin action in cultured muscle cells in response to serum starvation [11]. Further, activation of AMPK concomitant with ATM has been reported for a wide variety of cell types [12, 13, 14, 15, 16] with stimuli including depletion of mitochondria, hydrogen peroxide, and ionizing radiation. Similarly, activation of Akt—a protein with diverse functions in cell survival, protection of cardiac cells from hypertrophic stimuli, and fuel uptake and storage—by ionizing radiation requires functional ATM [17]. Likewise, activation of Akt by insulin-like growth factor
1 (IGF-1) and insulin is impaired in many cell types by inhibition or genetic ablation of ATM [5, 6, 7, 17, 18].

Chloroquine (CQ), a compound that activates ATM without causing DNA damage [19], has excitingly been shown to protect mice against aortic root atherosclerosis in high-fat fed mice [20]. Long-term CQ treatment also improved glucose tolerance in mouse genetic models of obesity [18] as well as decreased the risk of diabetes in patients with rheumatoid arthritis [21]. To understand the nature of CQ’s effects, especially in regard to a role for ATM, it is important to determine whether ATM is required for CQ’s actions. Accordingly, we hypothesized that CQ would activate the key metabolic regulators AMPK and Akt and that ATM would be required for these effects. This work also investigated effects of another ATM activator, resveratrol (RE), which like CQ has been reported to improve systemic glucose control in both mice and humans [22, 23].

Surprisingly, in our hands CQ activated both AMPK and Akt even in the presence of an ATM inhibitor or in cells expressing shRNA against ATM. CQ also decreased intracellular calcium levels and did not cause an increase in glucose uptake. Interestingly, while RE increased AMPK phosphorylation, it decreased Akt phosphorylation. Thus, the data suggest that CQ and RE could have metabolic effects beyond simple activation of ATM.

2. Materials and methods

2.1. Materials

Dulbecco’s modified Eagle’s medium (DMEM), trypsin/EDTA and phosphate-buffered saline (PBS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Penicillin/streptomycin (10,000 U penicillin/ml, 10 mg streptomycin/ml, and 0.025 mg fungizone/ml) was purchased from Gemini Bio-Products (Woodland, CA, USA). Antibodies against AMPK catalytic subunit, phosphorylated AMPK T172 (P-AMPK), phosphorylated acetyl Coenzyme A carboxylase (P-ACC), and phosphorylated Akt (P-Akt) S473 and T308 were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies against phosphorylated ATM S1981 (P-ATM) were from EMD Millipore (Billerica, MA, USA). Horseradish peroxidase-linked streptavidin and antibodies against ATM and tubulin were obtained from Sigma-Aldrich Corporation (St. Louis, MO, USA). Horseradish peroxidase-conjugated goat anti-rabbit and goat anti-mouse IgG were obtained from Pierce Biotechnology (Rockford, IL, USA). Chloroquine diphosphate (CQ), resveratrol (RE), and 1,2-Bis(2-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid tetrakis acetoxyethyl ester (BAPTA-AM) were purchased from Sigma-Aldrich. Dr. Graeme Smith (KuDOS Pharmaceuticals, Cambridge, UK) generously
provided the ATM inhibitor KU55933 (KU). Calcium Green-1 AM was from Invitrogen Life Technologies (Grand Island, NY).

2.2. Cell culture

C2C12 myoblasts were obtained from the American Type Culture Collection (Rockville, MD, USA). C2C12 cells were cultured in Dulbecco’s Minimum Essential Medium (DMEM) containing 10% FetalPlex (Gemini Bio-Products, Woodland, CA) and 1% penicillin/streptomycin. C2C12 cells were passaged by using a 5% trypsin, 0.02% EDTA solution every one to two days. Cells were differentiated for two days by incubating with DMEM containing 2% horse serum and 1% penicillin/streptomycin. Cells were grown in a humidified incubator with 5% CO₂ at 37 °C. For some experiments, myotubes were serum-starved by incubation with DMEM with antibiotic but without FetalPlex for three hours. C2C12 cell lines expressing green fluorescent protein (GFP) or short hairpin RNA to reduce ATM expression were described previously [5, 18].

2.3. Effects of CQ and resveratrol on phosphorylation of AMPK and Akt

Western blots were used to measure phosphorylation of AMPK and Akt after exposure to CQ and RE. Myotubes were incubated in DMEM containing 0 μM, 250 μM, 500 μM, or 750 μM CQ for 60 min. In separate experiments, myotubes were incubated in DMEM with 0 μM (vehicle: 0.1% DMSO), 50 μM, 100 μM, or 150 μM RE for one hour after a three hour serum starvation. After incubation, myotubes were placed on ice, media was aspirated, and cells were washed twice with phosphate-buffered saline. Cells were scraped in ice cold buffer containing 50 mM HEPES, pH 7.4, 2 mM Na₃VO₄, 150 mM NaF, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 0.5 μg/mL pepstatin and 1 mM phenylmethylsulfonyl fluoride. Cells were centrifuged at 14,000×g for 10 min, and supernatant was kept. Protein concentration of the supernatant was measured using a bicinchoninic assay from Thermo Scientific (Rockford, IL, USA).

To determine whether ATM plays a role in response to CQ and RE, C2C12 myotubes expressing shRNA against ATM or myotubes that were pretreated with the ATM inhibitor KU-55933 (KU) [24] were used. C2C12 cells expressing shRNA against ATM or GFP as a control were incubated in the presence or absence of 500 μM CQ for one hour. In separate experiments, C2C12 myotubes were pretreated for 30 min with either 10 μM or 5 μM KU-55933 (DMSO vehicle). Myotubes were then incubated in the absence or presence of 500 μM CQ or 150 μM RE with KU-55933 still present if it had been present in the pre-incubation. After an one hour exposure to CQ or RE, cells were lysed as described above.
2.4. Western blotting

Western blot procedures have been previously described [11]. Aliquots of cell lysates were diluted in Laemmli sample buffer containing dithiothreitol, boiled for 5 min, and separated on 4–20% Tris-HEPES-SDS polyacrylamide gels (Thermo Scientific) or 3–8% Tris-acetate gels (Life Technologies, Grand Island, NY, USA) alongside HiMark (Life Technologies) high molecular weight protein standards for analysis of ATM and P-ATM. After transfer to nitrocellulose and blocking in 5% nonfat dry milk in Tris-buffered saline, membranes were probed with the primary antibodies described in the Materials section, probed with secondary antibodies conjugated to horseradish peroxidase, and subjected to enhanced chemiluminescence analysis with Western Lightning reagents (Perkin Elmer, Waltham, MA, USA). ACC was detected with horseradish peroxidase conjugated to streptavidin, which binds the biotin moiety of ACC.

2.5. Glucose transport

Glucose transport assays were done as measured previously [5]. Myotubes were serum-starved for three hours before incubation in serum-free medium for 30 min in the presence or absence of 10 μM KU55933. After the preliminary incubation with vehicle (DMSO) or KU55933, the myotubes were incubated for one hour with 0 μM or 500 μM CQ, with DMSO or KU55933 still present. Myotubes were then rinsed with glucose-free HEPES-buffered saline and then assayed for rates of 2-deoxyglucose (2DG). Glucose transport assays were performed by incubating cells with glucose-free HBS containing radiolabeled 2-DG (3 μCi/ml, American Radiolabeled Chemical, Inc., St. Louis, MO, USA) for 10 min at room temperature. 10 μM cytochalasin B was used to measure GLUT independent glucose transport. After the 10 min incubation, the medium was aspirated, and the cells were rinsed twice with ice-cold saline. Cells were lysed in 0.2 N NaOH containing 0.2% SDS and 3H in samples was measured with a Tri-Carb 3110 TR Liquid Scintillation Analyzer (PerkinElmer, Waltham, MA). Glucose transport was normalized to protein concentrations of cell lysates measured by bicinchoninic acid (BCA) assay method (Pierce, Rockford, IL).

2.6. Intracellular calcium

Calcium measures were essentially as described for a plate reader-based intracellular calcium assay using Calcium Green-1 AM [25]. Myotubes in 96 well plates were incubated for 20 min at room temperature in phosphate buffered saline containing 5 mM glucose and 4 μM Calcium Green-1 AM, a membrane permeable fluorophore that increases in fluorescence emission as [Ca^{2+}] increases. Cells were washed with PBS, and then cells were incubated in a humidified 5% CO₂ incubator at 37 °C for 20 min in DMEM containing...
DMSO (vehicle) or 30 μM BAPTA-AM, a membrane permeable Ca$^{2+}$ chelator. Cells were washed with PBS and then incubated in the absence or presence of 0.5 mM CQ and in the presence or absence of BAPTA-AM for 60 min in HEPES-buffered saline (HBS: 5 mM glucose, 20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2.5 mM MgSO$_4$, and 1 mM CaCl$_2$). Fluorescence readings were taken with an excitation of 485 nm and emission of 590 nm and corrected for background fluorescence for cells treated identically except for preloading with Calcium Green-1 AM. In an additional experiment, cells were preloaded with Calcium Green-1 AM, incubated in the presence or absence of BAPTA-AM, and then exposed to CQ in calcium-free medium (PBS with 5 mM glucose).

2.7. Statistics

Data were analyzed by one-way ANOVA with post hoc Least Significant Difference (LSD) comparisons when P < 0.05 for the ANOVA.

3. Results

3.1. Effects of chloroquine on AMPK and Akt

As it has been suggested that ATM is upstream of AMPK [12, 13, 14, 15, 16], we hypothesized that the ATM activator CQ [19] would stimulate AMPK phosphorylation. Fig. 1A shows that myotubes incubated in concentrations of 250 and 500 μM CQ had a two and three fold increase of P-AMPK respectively, when compared to control cells (P < 0.05 and P < 0.001, n = 3/group). There was no further increase in P-AMPK for 750 μM CQ compared to 500 μM CQ. A direct downstream target of AMPK is ACC, the phosphorylation of which was measured as a marker for increased AMPK activity. Fig. 1B illustrates that 500 μM CQ caused better than a two fold increase in P-ACC compared to cells without CQ (P < 0.05, n = 3/group).

Phosphorylation of Akt was also measured since it has been reported that ATM plays a role in Akt activation by insulin or ionizing radiation [17]. Shown in Fig. 1C, exposure to 250 μM CQ caused a two fold increase in P-Akt at Ser 473 compared to the control cells (P < 0.05, n = 3/group). Fig. 1D shows that 250 μM CQ and 500 μM CQ also caused an increase in P-Akt at Thr 308 (P < 0.05, n = 3/group). Phosphorylation of S1981, ATM’s autophosphorylation site, was assessed as a marker for ATM activation. Fig. 2E shows that myotubes exposed to 500 μM CQ had an increased amount of phosphorylated ATM compared to the control (P < 0.05, n = 6/group), indicating that CQ activates ATM in myotubes.

In summary, Fig. 1 provides evidence that CQ is an ATM activator and increases phosphorylation of AMPK, ACC, and Akt in C2C12 myotubes.
3.2. Effects of resveratrol

We then used another reported ATM activator, RE, to examine whether results shown above were specific to CQ or could be generalized to other ATM activators. Fig. 2A shows that 150 μM RE increased phosphorylation of AMPK compared to vehicle treated controls (P < 0.05, n = 3/group). Phosphorylation of Akt at Thr 308 and Ser 473 in response to RE was also measured. Panels 2B

Fig. 1. Chloroquine increases phosphorylation of AMPK and Akt in C2C12 myotubes. Myotubes were incubated in indicated concentrations of chloroquine (CQ) for one hour. Proteins were extracted and subjected to western blot with specific antibodies for (A) phosphorylated AMPK (P-AMPK) normalized to AMPK, (B) P-ACC, normalized to streptavidin, (C) P-Akt S473 normalized to Akt, (D) P-Akt T308 normalized to Akt, and (E) P-ATM normalized to tubulin. Streptavidin was used to detect the biotin moiety of ACC. Representative blots are shown. Data are means ± SE; Symbols indicate statistical difference from control not exposed to CQ: *P < 0.05, †P < 0.001; n = 3/group for panels A–D and n = 6/group for panel E. Full images of western blots for Fig. 1 are available in the supplementary material as supplementary Figs. 1A–E.
and 2C illustrate that RE treatment does not increase phosphorylation of Akt at Ser 473 or T308 (n = 3/group), suggesting that incubation of myotubes with a purported ATM activator, RE, is not sufficient to stimulate phosphorylation of Akt. RE treatment not only did not increase Akt phosphorylation, but caused its inhibition (P < 0.05, n = 3/group). This phenomenon has been reported previously, though not in myotubes to our knowledge [26, 27].

3.3. Role of ATM in CQ and RE effects

To examine the role that ATM plays in CQ-stimulated phosphorylation of AMPK and Akt, we used C2C12 cell lines that expressed either shRNA against ATM (expression knocked down, KD) or green fluorescent protein (GFP). Fig. 3A shows that the KD cell line had an 80% decrease in ATM protein levels compared to protein levels in cell lines transduced with GFP (P < 0.05, n = 4/group). Fig. 3B shows that even in the KD cell lines, 500 μM CQ stimulated phosphorylation of AMPK (P < 0.05, n = 5/group). The shRNA against ATM also did not have an effect on CQ stimulated phosphorylation of Akt at Thr 308, as shown in Fig. 3C, (P < 0.05, n = 3/group). In summary, Fig. 3 shows that a decrease of ATM protein does not have an effect on CQ-stimulated phosphorylation of AMPK and Akt.

To confirm results that were shown with the KD cell line, a specific ATM inhibitor was used, KU55933 (KU), that has an IC50 concentration of 13 nM.
We used the compound at 10 μM, because previous research has shown that this concentration was sufficient to inhibit ATM [28]. In our hands, 1 μM KU is also sufficient to prevent ATM action in myotubes [11]. Pretreatment with 10 μM KU did not prevent CQ stimulated phosphorylation of AMPK, shown in Fig. 4A. (P < 0.05, n = 3/group). The addition of KU did not inhibit the phosphorylation of the downstream target of AMPK, ACC (P < 0.01, n = 3/group), as shown in Fig. 4B. Fig. 4C displays that KU did not interfere with CQ stimulated phosphorylation of Akt at Thr 308 (P < 0.05, n = 3/group). As shown in Fig. 4D, 5 μM KU had no effect on the increased phosphorylation of AMPK stimulated by RE (P < 0.05, n = 3/group). In summary, Fig. 4 demonstrates that the presence of ATM inhibitor, KU, does not have an effect on CQ and RE stimulated phosphorylation of AMPK or CQ stimulated phosphorylation of Akt.

Taken together, these results in Fig. 3 and Fig. 4 suggest that stimulation of AMPK and Akt by CQ is ATM-independent in C2C12 myotubes.
Fig. 4. Chloroquine and resveratrol stimulate phosphorylation of AMPK and chloroquine stimulates phosphorylation of Akt when ATM is inhibited. C2C12 myotubes were placed in medium containing either 10 μM KU or vehicle (DMSO) for 30 min. 500 μM CQ (CQ) was added to both KU-and DMSO-incubated cells. C2C12 lysates were analyzed by Western blot and probed for (A) P-AMPK normalized to AMPK, (B) P-ACC normalized ACC, (C) and P-Akt (THR308) normalized to Akt. (B) After serum starvation, myotubes were placed in medium containing either 5 μM KU or 1 vehicle (DMSO) for thirty minutes. Myotubes were then incubated with either DMSO (vehicle) or 150 μM RE for one hour. Myotubes were lysed and probed for P-AMPK normalized to AMPK. Representative blots are shown. Data are means ± SE; *indicates a statistically different value from corresponding cells not exposed to CQ, P < 0.05. n = 3/group for all panels. Full images of western blots for Fig. 4 are available in the supplementary material as supplementary Figs. 4A–D.
3.4. Effect of CQ on glucose uptake

CQ’s effect on glucose uptake in C2C12 myotubes was also measured. While the long term effects of CQ improving whole body metabolism is dogma [20, 21, 29, 30], research on CQ’s acute effects in cell culture have produced conflicting data. It has been reported that 100 μM CQ increases glucose transport in myotubes [31]. However, other papers have shown that 200 μM CQ inhibits insulin-stimulated GLUT4 translocation to the cell membrane in fat cells, and three hour CQ treatment had no effect on glucose uptake in human forearm muscle [32, 33]. Other researchers have shown that CQ has no effect on insulin-stimulated glucose transport in adipocytes [34]. In our hands, 500 μM CQ did not cause an increase in basal glucose transport and actually slightly inhibited it (Fig. 5A, P < 0.005, n = 9-10/group). The ATM inhibitor KU also inhibited glucose transport, a finding we have reported previously [3].

3.5. Effect of chloroquine on intracellular [Ca2+]

Recently, CQ has been identified as a ligand for MAS-related G protein coupled receptors (Mrgpr), including family members A3, A1, and X1 [35]. Binding of CQ to these receptors activates Ca2+ flow via transient receptor potential (TRP) cation channels and also activates phospholipase C activity that would stimulate IP3-mediated Ca2+ from intracellular calcium stores. At least two Mrgpr-responsive TRP cation channels, TRPA1 and TRPC3 are expressed in mouse skeletal muscle [36]. Increases in cytosolic calcium levels have been shown to activate Akt in myotubes [37, 38, 39], and there are Ca2+-dependent pathways for activation of AMPK [40]. Accordingly, we assessed intracellular Ca2+ using Calcium Green-1 AM, a membrane permeable fluorophore with fluorescence emission increasing as Ca2+ concentration increases. As shown in Fig. 5, CQ actually decreased intracellular calcium to the level achieved with BAPTA-AM, a membrane permeable Ca2+ chelator. This reduction of intracellular Ca2+ by CQ occurs even in Ca2+-free medium, suggesting that CQ decreases Ca2+ release from intracellular Ca2+ stores, such as the sarcoplasmic reticulum or lysosomes. Because CQ decreases intracellular Ca2+ – which is opposite from what would be expected if CQ were to act through a Mrgpr – a receptor mediated role of CQ in the activation of AMPK and Akt in myotubes seems unlikely. It seems likely that in our hands CQ inhibits glucose uptake by decreasing the abundance of intracellular calcium. This is consistent with a previous finding that BAPTA-AM suppresses glucose transport [41].

4. Discussion

Both CQ and RE are reported ATM activators [19, 42]. However, their roles in phosphorylation of AMPK have not been previously addressed in skeletal
muscle cells. This study provides evidence that CQ and RE increase phosphorylation of AMPK independent of ATM in C2C12 myotubes. Consistent with this, ATM did not play a role in CQ-stimulated phosphorylation of AMPK’s downstream target, ACC. This study also showed that CQ increases phosphorylation of Akt at S473 and T308 independent of ATM. The role of ATM was assessed by using either the ATM specific inhibitor, KU [24] or C2C12 cells expressing shRNA against ATM. Regardless of ATM inhibition or ATM deficiency, incubation with CQ increased phosphorylation of AMPK and Akt. Thus, CQ acts independently of ATM to activate AMPK and Akt in myotubes. An additional, novel aspect of the study is the demonstration that CQ decreases intracellular calcium concentration, probably through preventing Ca^{2+}.

Fig. 5. Chloroquine does not increase glucose transport but decreases intracellular [Ca^{2+}]. (A) Glucose transport was measured for 10 min in C2C12 myotubes. Both 1 hour of 0.5 mM CQ as well as 10 μM KU caused a decrease in glucose transport compared to the DMSO alone treatment. (B) Myotubes were preloaded with the fluorescent calcium sensor Calcium Green-1 AM and then incubated in the absence or presence of BAPTA-AM, a cell permeable calcium chelator, before exposure to 0.5 mM CQ for one hour. As indicated by Calcium Green fluorescence, CQ decreased intracellular Ca^{2+} to about the same level as BAPTA-AM both in medium containing Ca^{2+} (left) and Ca^{2+}-free medium (right) Symbols indicate a significant difference from control, *P < 0.05, **P < 0.005, ***P < 0.0005; n = 9–12 per group.
from intracellular stores. This decreased intracellular calcium possibly explains the failure of CQ to stimulate glucose transport.

The AMP-activated protein kinase (AMPK) is a heterotrimeric kinase that marshals responses to metabolic stress [40]. Downstream actions of AMPK include insulin-independent glucose disposal, increased insulin action, increased fat oxidation, and decreased fatty acid synthesis. Activation of AMPK with metformin before ischemia or during reperfusion in mice is cardioprotective, as demonstrated by substantial decrease in infarct size and preservation of ejection fraction, perhaps through AMPK’s activation of endothelial nitric oxide synthase (eNOS) [43]. The pre-ischemia protective effect of metformin was greater than the effect of metformin during reperfusion, suggesting that chronic treatment with an AMPK-activating compound could have cardioprotective value. In rats, activation of AMPK with Abbot Compound A769662 during ischemia decreased infarct size associated with increased glycogen synthase kinase 3β (GSK3β) phosphorylation [44].

A few earlier studies reported that ATM is an upstream activator of AMPK [13, 45]. For example, AMPK phosphorylation in response to insulin-like growth factor 1 (IGF1) was decreased in ATM-deficient HeLa cells [12]. Additional evidence suggests that ATM is required for 5-Aminomidazole-4-carboxamide ribonucleotide (AICAR)—stimulated phosphorylation of AMPK [13]. AICAR-stimulated phosphorylation of AMPK was blunted in ATM-deficient mouse embryonic fibroblasts or in the presence of the ATM inhibitor KU. AICAR-stimulated phosphorylation of AMPK was also inhibited in human HeLa cells in the presence of KU [13].

Our data suggest that there is a mechanism other than activation of ATM through which CQ and RE increase phosphorylation of AMPK. AMPK is activated by an increase in the AMP:ATP ratio [40]. Consistent with this idea, it has been shown that CQ inhibits mitochondrial proteins, such as cytochrome c oxidase, which would lead to a decrease in ATP production [46]. CQ has also been reported to be an uncoupling agent [47], and uncoupling of respiration from ATP synthesis could be a means by which CQ induces metabolic stress. Notably, in regard to the discussion of Akt that follows, mild uncoupling by use of dinitrophenol has been reported to increase Akt phosphorylation three fold in skeletal muscle [47]. RE exposure might also lead to decreased ATP production. For example, previous research has shown that RE inhibits ATP synthase [48]. Thus, it seems probable that CQ and RE could both activate AMPK by causing metabolic stress. If so, this would be a mechanism shared by a number of AMPK-activating compounds, such as metformin, quercetin, and berberine [40].

In addition to possibly inhibiting ATP production, our findings suggest that at higher concentrations, CQ and RE inhibit Akt. It could simply be that an
The increase of AMPK activation could lead to direct inhibition of Akt. This finding that AMPK agonists regulate Akt activation has been reported previously. Phenformin as well as AICAR both increased AMPK phosphorylation while decreasing Akt phosphorylation in neuroblastoma cells [49]. The AMPK agonist metformin also inhibits Akt phosphorylation in cervical cancer cells [50]. Our results and previous reports [51, 52, 53] have shown that RE does not increase phosphorylation of Akt and actually inhibits it. Other labs have also discovered this finding of RE inhibiting Akt phosphorylation in both breast cancer and liver cell lines [54, 55]. A possible explanation of how RE inhibits Akt is its effect of inhibiting cAMP phosphodiesterases [52]. Inhibition of phosphodiesterases leads to an increase in cAMP, which would inhibit localization of PDK1 at the plasma membrane, thus decreasing Akt activation [56].

Akt plays a central role in regulation of glucose transport in insulin-responsive tissues [57] and is a key positive regulator of glycogen synthesis through inhibition of glycogen synthase kinase 3β (GSK3β). In cardiomyocytes, GSK3β with a mutation preventing its activation by Akt is protective against cardiac hypertrophy and suppresses the protective effects of ischemic preconditioning [58]. In some tissue or cell types, ATM appears to be an upstream activator of Akt. For example, activating phosphorylation of Akt in response to insulin signaling is ATM dependent in human fibroblast cells [17], and IGF-1 failed to stimulate Akt phosphorylation in cultured myotubes when ATM was inhibited or knocked down with shRNA [18]. Likewise, Akt phosphorylation was reduced in the liver and aorta of mice heterozygous for a truncation mutation of ATM gene [30]. Finally, insulin-stimulated phosphorylation of Akt was blunted in fast twitch muscle of mice deficient in ATM [6], and ATM was reportedly required for full activation of Akt by insulin in cultured muscle cells [7]. Taken together, the reported roles of ATM upstream of Akt make activation of ATM an attractive strategy for improving a number of factors relevant to cardiovascular disease, including glucoregulation and cardioprotection.

On the surface, it is surprising that CQ stimulation of AMPK and Akt phosphorylation did not result in an increase in glucose transport. However, when taken in the light of CQ’s effects on intracellular calcium, this makes sense. Multiple labs have shown that chelation of intracellular calcium actually blocks insulin action in adipocytes and fibroblasts [41, 59, 60]. It has also been reported that basal glucose transport through GLUT1 requires cytosolic calcium ions in rat epithelial cells [61]. Thus, the decrease in intracellular calcium in the presence of CQ is a likely explanation for the lack of positive effect of CQ on glucose transport.

Given its ability to activate ATM, AMPK, and Akt—which together play prominent roles in responsive to genotoxic, oxidative, and metabolic stress, are
central regulators of fuel uptake, storage, and oxidation, and play key cardioprotective roles—CQ can exert positive metabolic effects, even in cell types in which ATM does not activate AMPK or Akt. The additional novel finding that CQ decreases intracellular calcium levels suggests that CQ could have important calcium-dependent vascular effects. For example, increased intracellular calcium has been linked to increased vasoconstriction and heart failure [62, 63]. In summary, cellular effects of CQ and RE are not limited to their activation of ATM. CQ especially can serve as an example compound able to modify disparate metabolic regulators, including ATM, AMPK, Akt, and intracellular calcium.

5. Conclusions

In summary, we have demonstrated that the ATM activator chloroquine stimulates AMPK and Akt phosphorylation in a manner that does not require ATM. Likewise, stimulation of Akt phosphorylation by the ATM activator resveratrol is independent of ATM. We have also shown that chloroquine causes a decrease in cytosolic Ca\(^{2+}\) concentration. Thus, we have uncovered multiple chloroquine effects that are separate from chloroquine’s activation of ATM.

Declarations

Author contribution statement

Larry D. Spears, Jonathan S. Fisher: Conceived and designed the experiments; performed the experiments; analyzed and interpreted the data; wrote the paper.

Andrew V. Tran, Charles Y. Qin, Supriya B. Hobbs, Cheryl A. Liang Burns, Nathaniel K. Royer: Conceived and designed the experiments; performed the experiments; analyzed and interpreted the data.

Zhihong Zhang: Conceived and designed the experiments; performed the experiments; analyzed and interpreted the data; contributed reagents, materials, analysis tools or data.

Lyle Ralston: Conceived and designed the experiments; performed the experiments; analyzed and interpreted the data; contributed reagents, materials, analysis tools or data; wrote the paper.

Conflict of interest statement

The authors declare no conflict of interest.
Funding statement

This work was supported by USPHS award R15DK080437 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to Jonathan Fisher. The manuscript content is solely the responsibility of the authors and does not necessarily represent the official views of NIDDK or the National Institutes of Health. The funding agency played no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Additional information

Supplementary content related to this article has been published online at 10.1016/j.heliyon.2016.e00083

Acknowledgements

Susan A. Spencer provided valuable technical advice.

References

[1] M.F. Lavin, Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer, Nat. Rev. Mol. Cell Biol. 9 (2008) 759–769.

[2] C. Cosentino, D. Grieco, V. Costanzo, ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair, EMBO J. 30 (2011) 546–555.

[3] S. Andrisse, G.D. Patel, J.E. Chen, A.M. Webber, L.D. Spears, R.M. Koehler, R.M. Robinson-Hill, J.K. Ching, I. Jeong, J.S. Fisher, ATM and GLUT1-S490 phosphorylation regulate GLUT1 mediated transport in skeletal muscle, PLoS One. 8 (2013) e66027.

[4] Y.A. Valentin-Vega, K.H. Maclean, J. Tait-Mulder, S. Milasta, M. Steeves, F.C. Dorsey, J.L. Cleveland, D.R. Green, M.B. Kastan, Mitochondrial dysfunction in ataxia-telangiectasia, Blood 119 (2012) 1490–1500.

[5] I. Jeong, A.Y. Patel, Z. Zhang, P.B. Patil, S.T. Nadella, S. Nair, L. Ralston, J.K. Hoormann, J.S. Fisher, Role of ataxia telangiectasia mutated in insulin signalling of muscle-derived cell lines and mouse soleus, Acta Physiol. (Oxf) 198 (2010) 465–475.

[6] J.K. Ching, L.D. Spears, J.L. Armon, A.L. Renth, S. Andrisse, R. Collins Lt, J.S. Fisher, Impaired insulin-stimulated glucose transport in ATM-deficient mouse skeletal muscle, Appl. Physiol. Nutr. Metab. 38 (2013) 589–596.
[7] M.J. Halaby, J.C. Hibma, J. He, D.Q. Yang, ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells, Cell. Signal. 20 (2008) 1555–1563.

[8] G.F. Merrill, E.J. Kurth, D.G. Hardie, W.W. Winder, AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle, Am. J. Physiol. 273 (1997) E1107–E1112.

[9] W.W. Winder, B.F. Holmes, D.S. Rubink, E.B. Jensen, M. Chen, J.O. Holloszy, Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle, J. Appl. Physiol. (1985) 88 (2000) 2219–2226.

[10] E.O. Ojuka, T.E. Jones, D.H. Han, M. Chen, B.R. Wamhoff, M. Sturek, J.O. Holloszy, Intermittent increases in cytosolic Ca2+ stimulate mitochondrial biogenesis in muscle cells, Am. J. Physiol. Endocrinol. Metab. 283 (2002) E1040–E1045.

[11] J.K. Ching, P. Rajguru, N. Marupudi, S. Banerjee, J.S. Fisher, A role for AMPK in increased insulin action after serum starvation, Am. J. Physiol. Cell Physiol. 299 (2010) C1171–C1179.

[12] A. Suzuki, G. Kusakai, A. Kishimoto, Y. Shimojo, T. Ogura, M.F. Lavin, H. Esumi, IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner, Biochem. Biophys. Res. Commun. 324 (2004) 986–992.

[13] Y. Sun, K.E. Connors, D.Q. Yang, AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner, Mol. Cell Biochem. 306 (2007) 239–245.

[14] X. Fu, S. Wan, Y.L. Lyu, L.F. Liu, H. Qi, Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation, PLoS One 3 (2008) e2009.

[15] A. Alexander, S.L. Cai, J. Kim, A. Nanez, M. Sahin, K.H. MacLean, K. Inoki, K.L. Guan, J. Shen, M.D. Person, D. Kusewitt, G.B. Mills, M.B. Kastan, C.L. Walker, ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS, Proc. Natl. Acad. Sci. USA 107 (2010) 4153–4158.

[16] T. Sanli, A. Rashid, C. Liu, S. Harding, R.G. Bristow, J.C. Cutz, G. Singh, J. Wright, T. Tsakiridis, Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells, Int. J. Radiat. Oncol. Biol. Phys. 78 (2010) 221–229.
[17] J.G. Viniegra, N. Martinez, P. Modirassari, J. Hernandez-Losa, C. Parada Cobo, V.J. Sanchez-Arevalo Lobo, C. Aceves-Luquero, L. Alvarez-Vallina, S. Ramon y Cajal, J.M. Rojas, R. Sanchez-Prieto, Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM, J. Biol. Chem. 280 (2005) 4029–4036.

[18] J.K. Ching, S.H. Luebbert, R.L. Collins, Z. Zhang, N. Marupudi, S. Banerjee, R.D. Hurd, L. Ralston, J.S. Fisher, Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle, Exp. Physiol. 98 (2013) 526–535.

[19] C.J. Bakkenist, M.B. Kastan, DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation, Nature 421 (2003) 499–506.

[20] B. Razani, C. Feng, C.F. Semenkovich, p53 is required for chloroquine-induced atheroprotection but not insulin sensitization, J. Lipid Res. 51 (2010) 1738–1746.

[21] M.C. Wasko, H.B. Hubert, V.B. Lingala, J.R. Elliott, M.E. Luggen, J.F. Fries, M.M. Ward, Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis, JAMA 298 (2007) 187–193.

[22] T. Szkudelski, K. Szkudelska, Anti-diabetic effects of resveratrol, Ann. N. Y. Acad. Sci. 1215 (2011) 34–39.

[23] K. Liu, R. Zhou, B. Wang, M.T. Mi, Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials, Am. J. Clin. Nutr. 99 (2014) 1510–1519.

[24] I. Hickson, Y. Zhao, C.J. Richardson, S.J. Green, N.M. Martin, A.I. Orr, P.M. Reaper, S.P. Jackson, N.J. Curtin, G.C. Smith, Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM, Cancer Res. 64 (2004) 9152–9159.

[25] K. Lin, W. Sadee, J.M. Quillan, Rapid measurements of intracellular calcium using a fluorescence plate reader, Biotechniques 26 (1999) 318–322 324-326.

[26] A.Y. Chan, V.W. Dolinsky, C.L. Soltys, B. Viollet, S. Baksh, P.E. Light, J.R. Dyck, Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt, J. Biol. Chem. 283 (2008) 24194–24201.

[27] H. Jiang, X. Shang, H. Wu, S.C. Gautam, S. Al-Holou, C. Li, J. Kuo, L. Zhang, M. Chopp, Resveratrol downregulates PI3 K/Akt/mTOR signaling pathways in human U251 glioma cells, J. Exp. Ther. Oncol. 8 (2009) 25–33.
[28] B.P. Chen, N. Uematsu, J. Kobayashi, Y. Lerenthal, A. Krempler, H. Yajima, M. Lobrich, Y. Shiloh, D.J. Chen, Ataxia telangiectasia mutated (ATM) is essential for DNA-PKcs phosphorylations at the Thr-2609 cluster upon DNA double strand break, J. Biol. Chem. 282 (2007) 6582–6587.

[29] J.K. Powrie, G.D. Smith, F. Shojaee-Moradie, P.H. Sonksen, R.H. Jones, Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus, Am. J. Physiol. 260 (1991) E897–1904.

[30] J.G. Schneider, B.N. Finck, J. Ren, K.N. Standley, M. Takagi, K.H. Maclean, C. Bernal-Mizrachi, A.J. Muslin, M.B. Kastan, C.F. Semenkovich, ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome, Cell Metab. 4 (2006) 377–389.

[31] M.J. Halaby, B.K. Kastein, D.Q. Yang, Chloroquine stimulates glucose uptake and glycogen synthase in muscle cells through activation of Akt, Biochem. Biophys. Res. Commun. 435 (2013) 708–713.

[32] E.J. Barrett, L.A. Jahn, D.M. Oliveras, D.A. Fryburg, Chloroquine does not exert insulin-like actions on human forearm muscle metabolism, Am. J. Physiol. 268 (1995) E820–E824.

[33] R. Romanek, R. Sargeant, M.R. Paquet, S. Gluck, A. Klip, S. Grinstein, Chloroquine inhibits glucose-transporter recruitment induced by insulin in rat adipocytes independently of its action on endomembrane pH, Biochem J. 296 (Pt 2) (1993) 321–327.

[34] Y. Oka, M. Kasuga, Y. Kanazawa, F. Takaku, Insulin induces chloroquine-sensitive recycling of insulin-like growth factor II receptors but not of glucose transporters in rat adipocytes, J. Biol. Chem. 262 (1987) 17480–17486.

[35] Q. Liu, Z. Tang, L. Surdenikova, S. Kim, K.N. Patel, A. Kim, F. Ru, Y. Guan, H.J. Weng, Y. Geng, B.J. Undem, M. Kollarik, Z.F. Chen, D.J. Anderson, X. Dong, Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus, Cell 139 (2009) 1353–1365.

[36] J. Kruger, C. Kunert-Keil, F. Bisping, H. Brinkmeier, Transient receptor potential cation channels in normal and dystrophic mdx muscle, Neuromuscul. Disord. 18 (2008) 501–513.

[37] J. Gorelick-Feldman, W. Cohick, I. Raskin, Ecdysteroids elicit a rapid Ca2+ flux leading to Akt activation and increased protein synthesis in skeletal muscle cells, Steroids 75 (2010) 632–637.
[38] T.E. Danciu, R.M. Adam, K. Naruse, M.R. Freeman, P.V. Hauschka, Calcium regulates the PI3K-Akt pathway in stretched osteoblasts, FEBS Lett. 536 (2003) 193–197.

[39] J.A. Drenning, V.A. Lira, Q.A. Soltow, C.N. Canon, L.M. Valera, D.L. Brown, D.S. Criswell, Endothelial nitric oxide synthase is involved in calcium-induced Akt signaling in mouse skeletal muscle, Nitric oxide: biology and chemistry/official journal of the Nitric Oxide Society. 21 (2009) 192–200.

[40] D.G. Hardie, AMPK a target for drugs and natural products with effects on both diabetes and cancer, Diabetes 62 (2013) 2164–2172.

[41] J.P. Whitehead, J.C. Molero, S. Clark, S. Martin, G. Meneilly, D.E. James, The role of Ca2+ in insulin-stimulated glucose transport in 3T3-L1 cells, J. Biol. Chem. 276 (2001) 27816–27824.

[42] A. Tyagi, R.P. Singh, C. Agarwal, S. Siriwardana, R.A. Sclafani, R. Agarwal, Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells, Carcinogenesis 26 (2005) 1978–1987.

[43] J.W. Calvert, S. Gundewar, S. Jha, J.J. Greer, W.H. Bestermann, R. Tian, D.J. Lefer, Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling, Diabetes 57 (2008) 696–705.

[44] M.A. Paiva, Z. Rutter-Locher, L.M. Goncalves, L.A. Providencia, S.M. Davidson, D.M. Yellon, M.M. Mocanu, Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury, Am. J. Physiol. Heart Circ. Physiol. 300 (2011) H2123–H2134.

[45] X. Duan, L. Ponomareva, S. Veeranki, D. Choubey, IFI16 induction by glucose restriction in human fibroblasts contributes to autophagy through activation of the ATM/AMPK/p53 pathway, PLoS One 6 (2011) e19532.

[46] P.D. Deepalakshmi, K. Parasakthy, S. Shanthi, N.S. Devaraj, Effect of chloroquine on rat liver mitochondria, Indian J. Exp. Biol. 32 (1994) 797–799.

[47] F.M. Cerqueira, F.R. Laurindo, A.J. Kowaltowski, Mild mitochondrial uncoupling and calorie restriction increase fasting eNOS, akt and mitochondrial biogenesis, PLoS One 6 (2011) e18433.
[48] J. Zheng, V.D. Ramirez, Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals, Brit. J. Pharmacol. 130 (2000) 1115–1123.

[49] T.D. King, L. Song, R.S. Jope, AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3, Biochem. Pharmacol. 71 (2006) 1637–1647.

[50] M.M. Yung, D.W. Chan, V.W. Liu, K.M. Yao, H.Y. Ngan, Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade, BMC Cancer 13 (2013) 327.

[51] A. Rashid, C. Liu, T. Sanli, E. Tsiani, G. Singh, R.G. Bristow, I. Dayes, H. Lukka, J. Wright, T. Tsakiridis, Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways, Radiat. Oncol. (London, England) 6 (2011) 144.

[52] S.J. Park, F. Ahmad, A. Philp, K. Baar, T. Williams, H. Luo, H. Ke, H. Rehmann, R. Taussig, A.L. Brown, M.K. Kim, M.A. Beaven, A.B. Burgin, V. Manganiello, J.H. Chung, Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases, Cell 148 (2012) 421–433.

[53] M.S. Banerjee, P.K. Chakraborty, S. Raha, Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70, PLoS One 5 (2010) e8719.

[54] E. Pozo-Guisado, M.J. Lorenzo-Benayas, P.M. Fernandez-Salguero, Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation, Int. J. Cancer 109 (2004) 167–173.

[55] J. Zhang, Resveratrol inhibits insulin responses in a SirT1-independent pathway, Biochem J. 397 (2006) 519–527.

[56] S. Kim, K. Jee, D. Kim, H. Koh, J. Chung, Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1, J. Biol. Chem. 276 (2001) 12864–12870.

[57] S.S. Bae, H. Cho, J. Mu, M.J. Birnbaum, Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B, J. Biol. Chem. 278 (2003) 49530–49536.

[58] H. Lal, F. Ahmad, J. Woodgett, T. Force, The GSK-3 family as therapeutic target for myocardial diseases, Circ. Res. 116 (2015) 138–149.
[59] H.A. Pershadsingh, D.L. Shade, D.M. Delfert, J.M. McDonald, Chelation of intracellular calcium blocks insulin action in the adipocyte, Proc. Natl. Acad. Sci. USA 84 (1987) 1025–1029.

[60] D.S. Worrall, J.M. Olefsky, The effects of intracellular calcium depletion on insulin signaling in 3T3-L1 adipocytes, Mol. Endocrinol. 16 (2002) 378–389.

[61] R.A. Quintanilla, O.H. Porras, J. Castro, L.F. Barros, Cytosolic [Ca(2+) modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells, Cell Calcium 28 (2000) 97–106.

[62] A. Sandoo, J.J. van Zanten, G.S. Metsios, D. Carroll, G.D. Kitas, The endothelium and its role in regulating vascular tone, Open Cardiovasc. Med. J. 23 (4) (2010) 302–312.

[63] A.R. Marks, Calcium and the heart: a question of life and death, J. Clin. Invest. 111 (2003) 597–600.